propanolol
Small moleculeexperimental
There are two isomers of propanol.1-Propanol, n-propanol, or propan-1-ol: CH3CH2CH2OH, the most common meaning 2-Propanol, isopropyl alcohol, isopropanol, or propan-2-ol: (CH3)2CHOH — Wikipedia
Clinical trial activity
17 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
2
Phase 4
4
Earliest trial started May 1, 2002 (NCT00515151)
Timeline
Indications
Approved for
Mechanism of action
- Beta-2 adrenergic receptorANTAGONIST
ADRB2 antagonist
- Beta-1 adrenergic receptorANTAGONIST
ADRB1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCO- Mol. weight
- 60.1 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPropanol ↗
- ChEMBLCHEMBL14687 ↗
Also known as
- 1-propanol
- 1-propanol
- 1-propanol
- 1-propanol
- 1-proponol
- 1-proponol
- ethylcarbinol
- ethylcarbinol
- n-propanol
- n-propanol
- n-propanol
- n-propyl alcohol
- n-propyl alcohol
- propan-1-ol
- propan-1-ol
- propanol
- propanol
- propanol
- propanol
- propanol
- propanol
- propyl alcohol
- propyl alcohol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06756126 | Phase 2 | Dec 30, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT06700499 | Phase 2 | Jul 8, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT06383468 | Phase 3 | Apr 30, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT06092762 | Phase 2 | Nov 6, 2023 | Akeso Pharmaceuticals, Inc. |
| NCT05859009 | N/A | Jul 1, 2023 | Unity Health Toronto |
| NCT05155020 | Phase 2 | Dec 1, 2021 | Akeso Pharmaceuticals, Inc. |
| NCT05427474 | Phase 3 | Dec 1, 2021 | Zagazig University |
| NCT06035354 | Phase 1/Phase 2 (Phase 2) | Nov 3, 2021 | Akeso Pharmaceuticals, Inc. |
| NCT05048056 | Phase 2 | Sep 10, 2021 | Akeso Pharmaceuticals, Inc. |
| NCT04683146 | Phase 4 | Mar 10, 2021 | Centro Ortopedico y Quirurgico del Pie, Universidad Complutense de Madrid |
| NCT05251610 | N/A | Nov 2, 2020 | Alex Ekwueme Federal University Teaching Hospital |
| NCT04538365 | Phase 4 | Oct 1, 2020 | Centro Ortopedico y Quirurgico del Pie, Universidad Complutense de Madrid |
| NCT04494763 | N/A | Aug 15, 2020 | Institute of Liver and Biliary Sciences, India |
| NCT04256174 | Early Phase 1 (Phase 1) | Feb 15, 2020 | Akeso Pharmaceuticals, Inc. |
| NCT03523650 | Phase 1 | Feb 7, 2018 | University of Virginia |
| NCT03393728 | Phase 4 | Sep 1, 2008 | University of Yaounde |
| NCT00515151 | Phase 4 | May 1, 2002 | University of Bern, University of Freiburg |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 8 | 8 | 3 | 2020 |
| Centro Ortopedico y Quirurgico del Pie | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Universidad Complutense de Madrid | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Alex Ekwueme Federal University Teaching Hospital | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Institute of Liver and Biliary Sciences, India | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Unity Health Toronto | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2002 |
| University of Freiburg | Academic/Hospital | 1 | 1 | 1 | 2002 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Yaounde | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Zagazig University | Academic/Hospital | 1 | 1 | 1 | 2021 |
11 organizations
Page 1 / 1